Minimally Invasive Management of GERD: Are We Ready For Prime Time? Presented on: September 21 st 2015 John E. Pandolfino, MD, MSCI Professor of Medicine.

Slides:



Advertisements
Similar presentations
Fisiopatologia del Reflusso e delle Plastiche Antireflusso XXIV Congr. Naz. ACOI, Montecatini 2005 Sez. Chirurgia Esofago- Gastrica U.Fumagalli I I I C.
Advertisements

A 50-year-old man with a history of symptomatic gastroesophageal reflux disease (GERD) has Barrett’s esophagus diagnosed on upper endoscopy. Which of.
Successful Strategies for Managing Acid-Related Disease in Primary Care Byron Cryer, MD Associate Professor of Medicine University of Texas Southwestern.
Pediatric Laproscopic Nissen Fundoplication
Sally Bowa, RN, MSN, FNP-C Dr. Hass Jassim,
WILLIAM J. SALYERS, JR., MD, MPH DIVISION CHIEF/MEDICAL DIRECTOR KU WICHITA GASTROENTEROLOGY ASSOCIATE PROGRAM DIRECTOR INTERNAL MEDICINE RESIDENCY Putting.
Gastroesophageal Reflux Disease (G.E.R.D.) Rory Loveland Paramedic class ’08-’09.
1 Literature Review Peter R. McNally, DO, FACP, FACG Lone Tree, Colorado.
The Non-Medical Treatments of the Gastroesophageal Reflux Disease (GERD) Joint Hospital Grand Round Prepared by Siu Yin Yu, Eva North District.
GastroEsophageal Reflux Disease (GERD)
Agency for Healthcare Research and Quality (AHRQ)
Gastro-Esophageal Reflux Disease
GERD Jaspreet Kaur 1488 MD 4.
High Value Care: GERD Sheetal Sharma, MBBS Assistant Professor of Clinical Medicine Associate Director of Endoscopic Quality Section of Advanced Therapeutic.
GASTROESOPHAGEAL REFLUX DISORDER
Paraesophageal Hiatal Hernias Bradley J. Phillips, MD Burn-Trauma-ICU Adults & Pediatrics.
Gastroesophageal Reflux Disease: Beyond Heartburn Annette Y. Kwon, M.D. Edward W. Holt, M.D. October 1, 2011.
Gastroesophageal Reflux Disease
Other treatments for GERD… Lee L Swanstrom MD, FACS Division of Minimally Invasive Surgery Legacy Health System Portland, OR.
Mohamed Aly Mokhles Assistant Prof of Hepatogastroenterology National Research Center. Egypt.
Esophageal Problems after Gastric Banding
Hiatal Hernia Repair, Vagotomy, Gastrectomy for GERD
Case # 2 Mr. Rendly.  39 y/o w/m here for initial evaluation  CC: “heartburn symptoms after each meal” This started a year ago, mostly in response to.
Gastroesophageal Reflux Disease (GERD)
gastroesophageal reflux disease GERD
Edward Auyang, MD, MS, FACS Assistant Professor of Surgery
New Techniques and Perspectives Presented on: May 17th 2014
Treating Complications Dysphagia, Leaks, Gastric Dysfunction Following Nissen Fundoplication Brant K. Oelschlager, MD University of Washington.
A gastroenterologist’s view of GERD and its pre-operative workup
 Gastro-Oesophageal Reflux Disorder ● Present in around 10% of the population ● Symptoms or damage to the mucosal lining of the distal oesophagus ● Caused.
Gastrointestinal Diseases Dr. Maha Arafah Pathology, 2012.
Update on Achalasia – Techniques and Outcomes William O. Richards MD, FACS Professor and Chair Department of Surgery and the Division of Gastrointestinal/Oncologic.
Re-operative anti-reflux surgery: When and How? Lee L. Swanstrom, MD Division of Minimally Invasive Surgery Legacy Health System Dept of Surgery, OR Health.
Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum Question.
Aviel Shapira M.D. Dept of Surgery A and Critical Care Soroka University Hospital Beer Sheva Israel New Anti-Reflux Procedures Financial Disclosure: Medical.
Brant K. Oelschlager, MD University of Washington
Collis Nissen for the Short Esophagus Collis Nissen for the Short Esophagus Bill Richards, MD, FACS Professor and Chair Surgery Bill Richards, MD, FACS.
GROUP D.  narrowing of the esophagus(distal) near the junction with the stomach (squamocolumnar jxn).  sequelae of gastroesophageal reflux– induced.
1 Clinical Overview Omeprazole Magnesium (Prilosec 1 TM ) June 21, 2002 Mark Avigan, MD CM Division of Gastrointestinal and Coagulation Drug Products CDER,
Gastro Esophageal Reflux Disease Presented for Sherman Hospital By Lawrence R. Kosinski, MD, MBA, FACG March 24 th, 2004.
Benign Esophageal Diseases Dr.Sami Alnassar MD, FRCSC.FCCP Dr.Sami Alnassar MD, FRCSC.FCCP.
Gastro Esophageal Reflux Disease (GERD)
Gastro-oesophageal reflux disease is the term used to describe a histopathological alteration resulting from episodes of reflux of acid, pepsin and occasionally.
Gastroesophageal Reflux Disease (GERD). * Definition: inflammation of the lower part of the esophagus due to abnormal reflux of gastric contents into.
Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors F Zerbib, A Duriez, S Roman, M.
Understanding Your Gastroesophageal Reflux Disease (GERD)
Bob Etemad, MD Medical Director of Endoscopy Main Line Health System.
Minimally Invasive Techniques for GERD
Agency for Healthcare Research and Quality (AHRQ)
Emanuele Asti, MD, FACS, Andrea Lovece, MD, Luigi Bonavina, MD, FACS
Gastro-Esophageal Reflux Disease.
A prospective study of endoscopic radiofrequency application (STRETTA) for gastroesophageal reflux disease: Early UK experience N Hamza, D Kamali, S Punnoose,
Dr. Firas Obeidat,MD.
Pathophysiology Factors associated with development of GERD:
Volume 148, Issue 2, Pages e5 (February 2015)
Do Endoscopic Antireflux Procedures Fit in the Current Treatment Paradigm of Gastroesophageal Reflux Disease?  John E. Pandolfino, Kumar Krishnan  Clinical.
A Modern Magnetic Implant for Gastroesophageal Reflux Disease
Volume 148, Issue 2, Pages e5 (February 2015)
Figure 3 Algorithm from working group describing
Persistent Reflux Symptoms in the Proton Pump Inhibitor Era: The Changing Face of Gastroesophageal Reflux Disease  Evan S. Dellon, Nicholas J. Shaheen 
HIATAL HERNIA BY: MUTHANNA AL-LAMI.
Persistent Reflux Symptoms in the Proton Pump Inhibitor Era: The Changing Face of Gastroesophageal Reflux Disease  Evan S. Dellon, Nicholas J. Shaheen 
Care of Patients with Esophageal Problems
Joel E. Richter  Clinical Gastroenterology and Hepatology 
Background Bariatric interventions offer a more efficacious and durable weight loss than non-surgical approaches Surgical weight loss procedures are limited.
GASTROESOPHAGEAL REFLUX DISEASE
Current Diagnosis and Management of Suspected Reflux Symptoms Refractory to Proton Pump Inhibitor Therapy Joel E. Richter, M.D. Gastroenterology & Hepatology.
GASTROESOPHAGEAL REFLUX
Presentation transcript:

Minimally Invasive Management of GERD: Are We Ready For Prime Time? Presented on: September 21 st 2015 John E. Pandolfino, MD, MSCI Professor of Medicine Feinberg School of Medicine, Northwestern University Chief, Division of Gastroenterology and Hepatology Northwestern Medicine Northwestern Memorial Hospital

Vakil N et al. Am J Gastroenterol 2006;101:1900 GERD is a condition which develops when the reflux of stomach content causes troublesome symptoms and / or complications Esophageal Syndromes Extra-esophageal Syndromes Symptomatic Syndromes Typical reflux syndrome Reflux chest pain syndrome Syndromes with Esophageal Injury Reflux esophagitis Reflux stricture Barrett's esophagus Adenocarcinoma Established Association Reflux cough Reflux laryngitis Reflux asthma Reflux dental erosions Proposed Association Sinusitis Pulmonary fibrosis Pharyngitis Recurrent otitis media

Primary pathophysiology Esophagitis Severity ≈ # of reflux events X Tissue sensitivity Causticity of gastric juice X Acid clearance Determinants of Reflux Severity

Symptom Triggers ≈ Reflux events X Tissue sensitivity Acidity of gastric juice X Acid clearance Symptom modulators ≈ Not a primary abnormality of GERD Determinants of Reflux Severity

Symptom Triggers ≈ Reflux events X Tissue sensitivity Acidity of gastric juice X Acid clearance PPI therapy of GERD is compensatory, not curative Symptom modulators ≈ Targets of PPI therapy Determinants of Reflux Severity

PPI efficacy for potential manifestations of GERD Estimates based on available RCT data PJ Kahrilas 2011 RM #46 v4/6/11 PJK 0% 100% 25% 50% 75% Esophagitis healing Mild Severe Heartburn relief Esophagitis NERD Regurgitation relief Chest pain (50% relief) GERD (+pH) GERD (-pH) Hoarseness (improved) GERD (-) Chronic cough (improved) Placebo Therapeutic gain

Symptom Triggers ≈ Reflux events Tissue sensitivity X Acidity of gastric juice X Acid clearance Symptom modulators ≈ PPI Failures Abnormal in number, composition, or volume refluxed Determinants of Refractory Reflux

Lateral projection PA projection 6x6mm Dimensions and Asymmetry of the EGJ Pandolfino JE, et al. Gastroenterology 2003;125: mmHg 4 mmHg -2 mmHg 0 mmHg 2 mmHg Distention pressure Normal GERD (-) HH GERD (+) HH -4 mmHg

EGJ Distensibility: Target for Therapy Kwiatek et al. J Gastrointest Surg Feb;14(2):268-76

Reflux-symptom Association on PPI Therapy Mechanism of PPI failure 168 patients with symptoms Symptoms 144 (85%) No symptoms 24 (15%) Positive SI 69 (48%) Negative SI 75 (52%) +SI acid 16 (11%) +SI non-acid 53 (37%) Functional Alternative DX Acid Breakthrough Non-Acid Reflux Maine et al. Gut Oct;55(10): ?

Antireflux Surgery in GERD Indications When antireflux surgery and PPI therapy are judged to offer similar efficacy in a patient with an esophageal GERD syndrome, PPI therapy should be recommended as initial therapy because of superior safety. I.When a patient with an esophageal GERD syndrome is responsive to, but intolerant of, acid suppressive therapy, antireflux surgery should be recommended as an alternative. II.Antireflux surgery for patients with an esophageal GERD syndrome with persistent troublesome symptoms, especially troublesome regurgitation, despite PPI therapy. i.Must have proven GERD. ii.The potential benefits of antireflux surgery should be weighed against the deleterious effect of new symptoms consequent from surgery, [dysphagia, gas bloat, IBS,].

Endoscopic Therapies for GERD Should have similar indications: If they work When endoscopic therapies and PPI therapy are judged to offer similar efficacy in a patient with an esophageal GERD syndrome, PPI therapy should be recommended as initial therapy because of superior safety. I.When a patient with an esophageal GERD syndrome is responsive to, but intolerant of, acid suppressive therapy, endoscopic therapies could be recommended as an alternative. II.Endoscopic therapies for patients with an esophageal GERD syndrome with persistent troublesome symptoms, especially troublesome regurgitation, despite PPI therapy. i.Must have proven GERD ii.The potential benefits of endoscopic therapies should be weighed against the deleterious effect of new symptoms consequent from the procedure, [dysphagia, gas bloat, IBS,].

Endoscopic Therapies for GERD Guidelines/Position Statements AGA GERD Guidelines 2008: The use of currently commercially available endoluminal antireflux procedures in the management of patients with an esophageal syndrome. (Insufficient evidence to recommend) ACG Guidelines 2013: The usage of current endoscopic therapy or transoral incisionless fundoplication cannot be recommended as an alternative to medical or traditional surgical therapy. (Strong recommendation, moderate level of evidence)

Minimally invasive treatments for GERD A brief history Stretta2001redesigned and active EndoCinch2000moribund Enteryx 2005voluntary recall 2005 Gatekeeper2004halted 2005 NDO Plicator2005halted 2008 Esophyx (TIF)2007active development Torax (Linx)2008 active development First PublicationStatus 2015

Endoscopic Therapies for GERD Stretta Technique: Safe and easy to use endoscopic procedure that is performed with minimal complications {< 30 minutes}.  Transient chest pain common Balloon placement Multiple treatments Remodeling and bulking of the EGJ

Study Mean LESPMean %AETPPI wd StrettaShamStrettaShamStrettaSham Corley (n=64)16.2 [10.6,23]18 [14.8,22.5]9.9[4,14.7]10.7[5.9,13]58%52% Coron (n=43)*n/an.a11.4(+/-6.3)8.8 (+/-6.1)15%0% Aziz (n=36)16.2 (+/- 4.5)15.9 (+/- 3.2)6.7( +/- 2.8)8.2 (+/- 3.1)16%0% Arts (n=22)16.3 (+/- 1.9)13.3 (+/- 2.0)159n/a * This study did not include a sham arm and compared Stretta to PPI and control Endoscopic Therapies for GERD Stretta Moderate symptom improvement with ? difference in objective findings.

Endoscopic Therapies for GERD Stretta Conclusions: Stretta appears to be safe and is the easiest to use. Stretta should be considered in proven GERD patients with no hernia who suffer from troublesome regurgitation, belching and cough despite PPI therapy. Downside: Durability Lack of true anatomical correction

Endoscopic Therapies for GERD Esophyx Technique: Endoscopic procedure that is similar to fundoplication (49 minutes) Fasteners deployed Device retrieval Valve with serosa-to- serosa approximation below Z-line

Endoscopic Therapies for GERD Esophyx P = RESPECT- Primary endpoint of troublesome regurgitation

Endoscopic Therapies for GERD Esophyx Screening 6-month p<0.01 TIF/placebo 6-month evaluation group (n=76, PP less 4 EF & 1 lost to f/u) ULN % Screening 6-month p=ns Sham/PPI 6-month evaluation group (n=28, PP less 9 EF & 1 lost to f/u)

RDQ reflux symptom scores (on medication) Screening TF/placebo 6-months TF/placebo Screening sham/PPI 6-months sham/PPI P < (0, 1.3) 3.1 (2.4, 3.8) 3.3 (2.5, 4.0) 0.9 (0.1, 2.0) P <.001 TIF/placebo (n=76, PP less 4 EF & 1 lost to f/u) Sham/PPI (n=28, PP less 9 EF & 1 lost to f/u) Endoscopic Therapies for GERD Esophyx

Significant adverse events Adverse eventOnsetDuration Severe epigastric/abdominal painDay 12 days Severe chest painDay 52 weeks Severe musculoskeletal painDay 51 day Moderate epigastric/abdominal painDay 14 weeks Moderate dysphagiaDay 18 days Mild dysphagiaDay 11 day Mild nauseaDay 11 day TF/placebo group (n=87) Severe nauseaDay 12 days Sham/omeprazole group (n=42) Endoscopic Therapies for GERD Esophyx

Conclusions: TF appears to be safe, without fundoplication side effects. TF should be considered in proven GERD patients with small or absent hiatal hernia who suffer from troublesome regurgitation, despite PPI therapy. Downside: Durability Ease of use Still not helpful in patients without hernia

Minimally Invasive Therapy for GERD LINX Bonavina L et al. J Gastrointest Surg 2008;12:2133 In position just below Z-line

Lx 11 v2/16/13 PJK Ganz R, et al N Engl J Med 2013;368:719-27

Magnetic sphincter augmentation 3 year results of uncontrolled trial Lx 12 v1/29/14 PJK PPI useRegurgitation Esophagitis Dysphagia Ganz R, et al N Engl J Med 2013;368:719-27

Magnetic sphincter augmentation Primary outcome- pH-metry normalization Lx 13 v1/29/14 PJK Ganz R, et al N Engl J Med 2013;368:719-27

Minimally invasive Therapy for GERD LINX Conclusions: Appears to be as effective as fundoplication and is reversible. May be reserved for proven GERD patients with and without hernia who require treatment beyond PPI therapy. Downside No sham controlled data yet. Still an implant- 3% of 4000 cases have been explanted

EGD and possible reflux testing if EGD (-) and symptoms continue Define Phenotype-Reflux Testing Proven Refractory Reflux Hernia Proven Refractory Reflux Normal Anatomy Consider Intervention* Stretta/Esophyx/LINX? Consider Intervention* Hernia repair LINX/ Fundoplication Not Reflux Alternative Diagnosis* Neuromodulator Document Compliance Consider motility (HRIM) testing for atypical presentation Rule out eating disorder/rumination * R/O major motility disorder, belching syndrome and gastric emptying issue if not done already Lifestyle modifications Behavioral Intervention Optimize medications Lifestyle modifications Behavioral Intervention Optimize medications Northwestern Refractory GERD Approach Heartburn, Regurgitation, Chest Pain Lifestyle modifications Behavioral Intervention Stop PPI Baclofen/Neuromodulator

Thank You